Tavaglione, Federica
University of California San Diego
6 papers on CoChatORCID 0000-0002-1720-4355
Most cited papers
- Verified
Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance
Hutchison, A. L., Tavaglione, F., Romeo, S., & Charlton, M. (2023) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects
Cited by 250
- Verified
A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores
De Vincentis, A., Tavaglione, F., Jamialahmadi, O., Picardi, A., Antonelli Incalzi, R., Valenti, L., Romeo, S., & Vespasiani-Gentilucci, U. (2022) · Clinical Gastroenterology and Hepatology
Liver Disease Diagnosis and TreatmentGenetic Associations and Epidemiology
Cited by 158
- Verified
Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease
Jamialahmadi, O., Mancina, R. M., Ciociola, E., Tavaglione, F., Luukkonen, P. K., Baselli, G., Malvestiti, F., Thuillier, D., Raverdy, V., Männistö, V., et al. (2021) · Gastroenterology
Liver Disease Diagnosis and TreatmentGenetic Associations and Epidemiology
Cited by 148
- Verified
Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women
Cherubini, A., Ostadreza, M., Jamialahmadi, O., Pelusi, S., Rrapaj, E., Casirati, E., Passignani, G., Norouziesfahani, M., Sinopoli, E., Baselli, G., et al. (2023) · Nature Medicine
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 136
- Verified
Rare ATG7 genetic variants predispose patients to severe fatty liver disease
Baselli, G. A., Jamialahmadi, O., Pelusi, S., Ciociola, E., Malvestiti, F., Saracino, M., Santoro, L., Cherubini, A., Dongiovanni, P., Maggioni, M., et al. (2022) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentAutophagy in Disease and Therapy
Cited by 97
- Verified
Review Article: GLP ‐1 Receptor Agonists and Glucagon/ GIP / GLP ‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics
Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management
Cited by 47
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free